# Venus MedTech (HangZhou)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/venus-medtech-hangzhou

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.venusmedtech.com
- Total disclosed funding: $18M
- Latest round: Series B (Jul 1, 2013)
- Investors on record: 3

## About

Founded in 2009 and based in Hangzhou, China, Venus MedTech (HangZhou) Inc. develops an artificial cardiac valve system used in the treatment of aortic stenosis in the form of a catheter-based technology. In May 2018, the firm closed a venture funding. In December 2019, the company was listed on the Hong Kong Stock Exchange. Its stock code is 02500. As of the end of August 2024, it has more than 800 patents and patent applications, including more than 400 authorized invention patents.

The company's main product is the percutaneous interventional heart valve system (TAVR) product. TAVR products include VenusA-Valve, VenusA-Plus, VenusA-Pro and other models. The company provides solutions for aortic valve disease, pulmonVenus MedTech (HangZhou) Inc.ary valve disease and hypertension.

The company’s revenue is generated by providing percutaneous interventional heart valve prosthesis (TAVR) products.

## Funding rounds

- Series B, Jul 1, 2013 — DNV Capital
- Series A, Jun 1, 2013, $18M — Qiming Venture Partners
- Series A, Jun 1, 2011 — CDF-Capital

## Investors

- CDF-Capital (https://capitalatlas.ai/funds/cdf-capital) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series B